ATE356119T1 - Pyrimidinone als melanin concentrating hormone receptor 1 - Google Patents

Pyrimidinone als melanin concentrating hormone receptor 1

Info

Publication number: ATE356119T1
Authority: AT; Austria
Prior art keywords: pyrimidinone; hormone receptor; concentrating hormone; melanin concentrating; melanin
Prior art date: 2001-10-15

Application number

AT02801692T

Other languages

English (en)

Inventor

Andrew J Carpenter

Oper Joel P C

Anthony L Handlon

Donald L Hertzog

Clifton E Hyman

Yu C Guo

Jason D Speake

David Richard Witty

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-15

Filing date

2002-10-15

Publication date

2007-03-15

2002-10-15 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE356119T1 publication Critical patent/ATE356119T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D257/12—Six-membered rings having four nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Steroid Compounds (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT02801692T 2001-10-15 2002-10-15 Pyrimidinone als melanin concentrating hormone receptor 1 ATE356119T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0124627.1A GB0124627D0 (en)	2001-10-15	2001-10-15	Novel compounds

Publications (1)

Publication Number	Publication Date
ATE356119T1 true ATE356119T1 (de)	2007-03-15

Family

ID=9923785

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02801692T ATE356119T1 (de)	2001-10-15	2002-10-15	Pyrimidinone als melanin concentrating hormone receptor 1
AT02801693T ATE349434T1 (de)	2001-10-15	2002-10-15	Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02801693T ATE349434T1 (de)	2001-10-15	2002-10-15	Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten

Country Status (21)

Country	Link
EP (2)	EP1442025B1 (de)
JP (2)	JP2005508966A (de)
KR (2)	KR20040045833A (de)
CN (2)	CN1596247A (de)
AT (2)	ATE356119T1 (de)
BR (2)	BR0213040A (de)
CA (2)	CA2463508A1 (de)
CO (2)	CO5580778A2 (de)
CZ (2)	CZ2004498A3 (de)
DE (2)	DE60218721T2 (de)
ES (2)	ES2283647T3 (de)
GB (1)	GB0124627D0 (de)
HU (2)	HUP0402335A3 (de)
IL (2)	IL161074A0 (de)
MX (2)	MXPA04003534A (de)
NO (2)	NO20041503L (de)
NZ (1)	NZ531911A (de)
PL (2)	PL370587A1 (de)
RU (1)	RU2004110053A (de)
WO (2)	WO2003033476A1 (de)
ZA (2)	ZA200402672B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005510563A (ja)	2001-11-26	2005-04-21	シェーリング　コーポレイション	肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト
EP1450801A4 (de)	2001-11-27	2010-10-27	Merck Sharp & Dohme	2-aminochinolin-verbindungen
DE10238865A1 (de) *	2002-08-24	2004-03-11	Boehringer Ingelheim International Gmbh	Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en)	2002-10-31	2008-04-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20060194871A1 (en) *	2003-04-11	2006-08-31	Barvian Kevin K	Heterocyclic mchr1 antagoists
CN100418965C (zh) *	2003-08-15	2008-09-17	万有制药株式会社	咪唑并吡啶衍生物
KR100747042B1 (ko) *	2003-08-19	2007-08-07	솔젠트 (주)	신물질６-메틸-３-펜에틸-３,４-디히드로-１ｈ-큐나졸린-２-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물
CN1871242A (zh) *	2003-10-23	2006-11-29	葛兰素集团有限公司	作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物
US7592373B2 (en)	2003-12-23	2009-09-22	Boehringer Ingelheim International Gmbh	Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
EP1717230B1 (de) *	2004-02-13	2014-08-06	Msd K.K.	4-oxopyrimidinderivat mit kondensiertem ring
DE102004010893A1 (de) *	2004-03-06	2005-09-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7605176B2 (en)	2004-03-06	2009-10-20	Boehringer Ingelheim International Gmbh	β-ketoamide compounds with MCH antagonistic activity
WO2005097127A2 (en)	2004-04-02	2005-10-20	Merck & Co., Inc.	Method of treating men with metabolic and anthropometric disorders
US7524862B2 (en)	2004-04-14	2009-04-28	Boehringer Ingelheim International Gmbh	Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de)	2004-04-14	2005-11-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006066174A1 (en)	2004-12-17	2006-06-22	Eli Lilly And Company	Thiazolopyridinone derivates as mch receptor antagonists
JP4211867B2 (ja) *	2005-02-14	2009-01-21	萬有製薬株式会社	４（３ｈ）−キナゾリノン誘導体の結晶
JP5000490B2 (ja) *	2005-04-28	2012-08-15	武田薬品工業株式会社	チエノピリミドン化合物
WO2007011286A1 (en) *	2005-07-15	2007-01-25	Astrazeneca Ab	Therapeutic agents
UA91560C2 (ru) *	2005-08-31	2010-08-10	Селджин Корпорэйшн	Соединения ряда изоиндолимидов, их композиция и применение
PT1939204E (pt) *	2005-10-19	2013-03-14	Kissei Pharmaceutical	Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
US7745447B2 (en) *	2005-10-26	2010-06-29	Bristol-Myers Squibb Company	Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en)	2005-10-26	2013-12-31	Bristol-Myers Squibb Company	Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
CN101341135B (zh)	2005-12-21	2013-08-14	詹森药业有限公司	治疗mch-1介导的疾病的取代的吡嗪酮衍生物
US7553836B2 (en) *	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
KR20080096670A (ko)	2006-02-15	2008-10-31	사노피-아벤티스	신규한 아미노 알콜-치환된 아릴티에노피리미디논, 이의 제조 방법 및 약제로서 이의 용도
RU2008136898A (ru) *	2006-02-15	2010-03-20	Санофи-Авентис (Fr)	Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
CA2636617A1 (en)	2006-02-15	2007-08-23	Lothar Schwink	Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
KR20080095879A (ko)	2006-02-15	2008-10-29	사노피-아벤티스	신규 아자사이클릴-치환된 아릴티에노피리미디논, 이의 제조 방법 및 이의 약물로서의 용도
WO2007142217A1 (ja) *	2006-06-07	2007-12-13	Banyu Pharmaceutical Co., Ltd.	１－フェニルピリドン誘導体
EA015127B1 (ru) *	2006-06-08	2011-06-30	Эли Лилли Энд Компани	Антагонисты мсн-рецепторов
CA2652524A1 (en)	2006-06-08	2007-12-21	Eli Lilly And Company	Novel mch receptor antagonists
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2121703A4 (de) *	2006-08-18	2011-12-28	Astrazeneca Ab	Thienopyrimidin-4-on- und thienopyridazin-7-onderivate als mch-rl-antagonisten
CA2664112C (en)	2006-12-05	2015-02-17	Janssen Pharmaceutica N.V.	Novel substituted diaza-spiro-pyridinone derivatives for use in mch-1 mediated diseases
KR20090082484A (ko) *	2006-12-14	2009-07-30	일라이 릴리 앤드 캄파니	5-[4-(아제티딘-3-일옥시)-페닐]-2-페닐-5ｈ-티아졸로[5,4-ｃ]피리딘-4-온 유도체 및 ｍｃｈ 수용체 길항제로서의 이들의 용도
NZ578096A (en)	2007-01-10	2011-11-25	Albany Molecular Res Inc	5-pyridinone substituted indazoles
JP2010525077A (ja) *	2007-04-25	2010-07-22	ブリストル−マイヤーズスクイブカンパニー	非塩基性メラニン凝集ホルモン受容体−１アンタゴニスト
EP2998314B1 (de)	2007-06-04	2020-01-22	Bausch Health Ireland Limited	Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DE102007028925A1 (de)	2007-06-22	2008-12-24	Saltigo Gmbh	Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
CA2693377A1 (en)	2007-07-21	2009-01-29	Albany Molecular Research, Inc.	5-pyridinone substituted indazoles
JP5632612B2 (ja) *	2007-12-05	2014-11-26	あすか製薬株式会社	ラクタム化合物又はその塩及びｐｐａｒ活性化剤
PE20091928A1 (es) *	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2009149279A2 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009307884B2 (en)	2008-10-22	2014-07-31	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2689707A1 (en)	2009-11-16	2011-05-16	Jean-Simon Diallo	Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
MX2012001729A (es)	2009-08-26	2012-06-13	Sanofi Sa	Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012036233A1 (ja) *	2010-09-17	2012-03-22	塩野義製薬株式会社	メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
AU2012220595B2 (en)	2011-02-25	2015-07-16	Merck Sharp & Dohme Llc	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
KR101236188B1 (ko) *	2011-03-10	2013-02-22	한국화학연구원	신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
HUP1100241A3 (en)	2011-05-06	2013-12-30	Richter Gedeon Nyrt	Oxetane substituted pyrimidones
NO3175985T3 (de)	2011-07-01	2018-04-28
UY34171A (es)	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
JP2015525782A (ja)	2012-08-02	2015-09-07	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病性三環式化合物
EP2958562A4 (de)	2013-02-22	2016-08-10	Merck Sharp & Dohme	Antidiabetische bicyclische verbindungen
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
CN113388007A (zh)	2013-06-05	2021-09-14	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
AR100711A1 (es) *	2014-06-05	2016-10-26	Bayer Cropscience Ag	Compuestos bicíclicos como agentes para combatir parásitos
SG11201804901WA (en)	2015-12-22	2018-07-30	SHY Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
MX2019001762A (es) *	2016-08-12	2019-06-12	Bayer Cropscience Ag	Metodo para la preparacion de derivados de 4-sustituido-2,3-dihidr o-1-benzofurano mediante la ciclacion de sales de 2-(2-diazonio-6-sustituido fenil)-etanol.
WO2018049328A1 (en) *	2016-09-12	2018-03-15	Numerate, Inc.	Bicyclic compounds useful as gpr120 modulators
EP3509587B1 (de)	2016-09-12	2023-12-06	Valo Health, Inc.	Als gpr120-modulatoren nützliche monocyclische verbindungen
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
EA201992780A1 (ru)	2017-06-21	2020-06-02	ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи	Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019063704A1 (en)	2017-09-29	2019-04-04	Bayer Aktiengesellschaft	SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
WO2019063708A1 (en)	2017-09-29	2019-04-04	Bayer Aktiengesellschaft	SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
CN110563730B (zh) *	2019-07-29	2022-03-25	江苏理工学院	高纯度n10-三氟乙酰蝶酸的制备方法
US12180193B2 (en)	2020-08-28	2024-12-31	Arvinas Operations, Inc.	Accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN113651800B (zh) *	2021-09-07	2022-08-19	山东铂源药业股份有限公司	一种甲磺酸奥希替尼的制备方法
US11957759B1 (en)	2022-09-07	2024-04-16	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL137227B2 (en) *	1984-03-28	1986-05-31	Univ Lodzki	Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids
HUP0301101A3 (en) *	1996-12-31	2009-03-30	Reddy S Res Foundation	Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP1218336A2 (de) *	1999-09-20	2002-07-03	Takeda Chemical Industries, Ltd.	Antagonisten des melanin-konzentrierenden hormons

2001
- 2001-10-15 GB GBGB0124627.1A patent/GB0124627D0/en not_active Ceased
2002
- 2002-10-15 IL IL16107402A patent/IL161074A0/xx unknown
- 2002-10-15 ES ES02801692T patent/ES2283647T3/es not_active Expired - Lifetime
- 2002-10-15 EP EP02801692A patent/EP1442025B1/de not_active Expired - Lifetime
- 2002-10-15 CN CNA028235932A patent/CN1596247A/zh active Pending
- 2002-10-15 AT AT02801692T patent/ATE356119T1/de not_active IP Right Cessation
- 2002-10-15 JP JP2003536220A patent/JP2005508966A/ja active Pending
- 2002-10-15 CZ CZ2004498A patent/CZ2004498A3/cs unknown
- 2002-10-15 CA CA002463508A patent/CA2463508A1/en not_active Abandoned
- 2002-10-15 KR KR10-2004-7005546A patent/KR20040045833A/ko not_active Application Discontinuation
- 2002-10-15 ES ES02801693T patent/ES2279009T3/es not_active Expired - Lifetime
- 2002-10-15 NZ NZ531911A patent/NZ531911A/en unknown
- 2002-10-15 MX MXPA04003534A patent/MXPA04003534A/es unknown
- 2002-10-15 HU HU0402335A patent/HUP0402335A3/hu unknown
- 2002-10-15 DE DE60218721T patent/DE60218721T2/de not_active Expired - Fee Related
- 2002-10-15 CN CNA028204522A patent/CN1571774A/zh active Pending
- 2002-10-15 JP JP2003536216A patent/JP2005510487A/ja active Pending
- 2002-10-15 IL IL16087202A patent/IL160872A0/xx unknown
- 2002-10-15 CA CA002463509A patent/CA2463509A1/en not_active Abandoned
- 2002-10-15 PL PL02370587A patent/PL370587A1/xx not_active Application Discontinuation
- 2002-10-15 EP EP02801693A patent/EP1436267B1/de not_active Expired - Lifetime
- 2002-10-15 WO PCT/US2002/032739 patent/WO2003033476A1/en active IP Right Grant
- 2002-10-15 KR KR1020047005548A patent/KR20050043724A/ko not_active Withdrawn
- 2002-10-15 AT AT02801693T patent/ATE349434T1/de not_active IP Right Cessation
- 2002-10-15 BR BR0213040-8A patent/BR0213040A/pt not_active IP Right Cessation
- 2002-10-15 CZ CZ2004499A patent/CZ2004499A3/cs unknown
- 2002-10-15 BR BR0213242-7A patent/BR0213242A/pt not_active Application Discontinuation
- 2002-10-15 HU HU0402346A patent/HUP0402346A2/hu unknown
- 2002-10-15 DE DE60217147T patent/DE60217147T2/de not_active Expired - Fee Related
- 2002-10-15 PL PL02370138A patent/PL370138A1/xx not_active Application Discontinuation
- 2002-10-15 MX MXPA04003532A patent/MXPA04003532A/es unknown
- 2002-10-15 RU RU2004110053/04A patent/RU2004110053A/ru not_active Application Discontinuation
- 2002-10-15 WO PCT/US2002/032740 patent/WO2003033480A1/en active IP Right Grant
2004
- 2004-04-05 ZA ZA200402672A patent/ZA200402672B/en unknown
- 2004-04-13 ZA ZA200402814A patent/ZA200402814B/en unknown
- 2004-04-13 NO NO20041503A patent/NO20041503L/no not_active Application Discontinuation
- 2004-04-13 NO NO20041504A patent/NO20041504L/no not_active Application Discontinuation
- 2004-04-14 CO CO04034243A patent/CO5580778A2/es not_active Application Discontinuation
- 2004-04-14 CO CO04034241A patent/CO5580779A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200402814B (en)	2005-04-13
GB0124627D0 (en)	2001-12-05
EP1436267B1 (de)	2006-12-27
BR0213040A (pt)	2004-10-05
WO2003033480A1 (en)	2003-04-24
NO20041504L (no)	2004-05-13
ES2283647T3 (es)	2007-11-01
CN1596247A (zh)	2005-03-16
RU2004110053A (ru)	2005-10-20
PL370587A1 (en)	2005-05-30
JP2005508966A (ja)	2005-04-07
DE60218721T2 (de)	2007-11-15
BR0213242A (pt)	2004-09-28
PL370138A1 (en)	2005-05-16
DE60217147D1 (de)	2007-02-08
DE60218721D1 (en)	2007-04-19
CN1571774A (zh)	2005-01-26
NZ531911A (en)	2004-11-26
ATE349434T1 (de)	2007-01-15
IL160872A0 (en)	2004-08-31
KR20040045833A (ko)	2004-06-02
HUP0402335A2 (hu)	2005-02-28
MXPA04003532A (es)	2004-07-22
ES2279009T3 (es)	2007-08-16
CZ2004498A3 (cs)	2004-07-14
CA2463508A1 (en)	2003-04-24
EP1442025B1 (de)	2007-03-07
NO20041503L (no)	2004-05-13
EP1436267A1 (de)	2004-07-14
JP2005510487A (ja)	2005-04-21
CA2463509A1 (en)	2003-04-24
IL161074A0 (en)	2004-08-31
HUP0402346A2 (hu)	2005-02-28
CZ2004499A3 (cs)	2004-08-18
EP1442025A1 (de)	2004-08-04
KR20050043724A (ko)	2005-05-11
MXPA04003534A (es)	2004-07-22
CO5580778A2 (es)	2005-11-30
ZA200402672B (en)	2005-04-05
HUP0402335A3 (en)	2006-02-28
WO2003033476A1 (en)	2003-04-24
DE60217147T2 (de)	2007-10-31
CO5580779A2 (es)	2005-11-30

Publication	Publication Date	Title
ATE356119T1 (de)	2007-03-15	Pyrimidinone als melanin concentrating hormone receptor 1
CY1113054T1 (el)	2016-04-13	Παραγωγα διαμινης
CY1106247T1 (el)	2011-06-08	Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
ATE372768T1 (de)	2007-09-15	N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
ATE100448T1 (de)	1994-02-15	Substituierte chinazolinone als angiotensin iiantagonisten.
CY1109886T1 (el)	2014-09-10	Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
DE69803907D1 (de)	2002-03-28	Fungizide 2-Methoxybenzophenone
BR0210078A (pt)	2004-06-22	Composto, uso do mesmo, e, formulação farmacêutica
NO20041493L (no)	2004-04-13	Kjemiske forbindelser.
MXPA03007142A (es)	2004-05-24	Derivados de carbolina.
MXPA03002911A (es)	2003-09-10	Compuestos quimicos.
DK1456212T3 (da)	2007-04-02	6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
ATE411287T1 (de)	2008-10-15	Neue metallproteinaseinhibitoren
BRPI0516242A (pt)	2008-08-26	compostos tieno-pirimidina tendo atividade fungicida
SV2003000981A (es)	2003-07-29	Fenil-heterociclil-eteres ref. pcs10973
NO994135L (no)	1999-10-22	Kinoksalindioner
EA200601030A1 (ru)	2006-10-27	7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ
DE60039695D1 (de)	2008-09-11	Antifucoidan antikörper
DE60211018D1 (de)	2006-06-01	Fungizide thiazolderivate
DK1497256T3 (da)	2010-09-27	Substituerede 1,5-diaminopentan-3-ol-forbindelser
PT1140932E (pt)	2004-08-31	Derivados de 1,8-benzonaftiridina

Legal Events

Date	Code	Title	Description
2007-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties